Item 7.01 Regulation FD

On October 1, 2020, representatives of Krystal Biotech, Inc., a Delaware corporation (the "Company"), made a presentation to the 2020 Virtual debra Care Conference, which included an update on the Company's GEM-3 clinical trials for beremagene geperpavec ("B-VEC"). A copy of the Company's presentation is attached as Exhibit 99.1 hereto and incorporated by reference herein.

In accordance with General Instruction B.2 to Form 8-K, the information contained in this Current Report, including Exhibit 99.1 attached hereto, is being "furnished" and not "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
  No.        Description

99.1           Krystal Biotech, Inc. Presentation to the 2020 Virtual debra Care
             Conference, dated October 1, 2020

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses